Endogenous matrix-derived inhibitors of angiogenesis

12Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Endogenous inhibitors of angiogenesis are proteins or fragments of proteins that are formed in the body, which can inhibit the angiogenic process. These molecules can be found both in the circulation and sequestered in the extracellular matrix (ECM) surrounding cells. Many matrix-derived inhibitors of angiogenesis, such as endostatin, tumstatin, canstatin and arresten, are bioactive fragments of larger ECM molecules. These substances become released upon proteolysis of the ECM and the vascular basement membrane (VBM) by enzymes of the tumor microenvironment. Although the role of matrix-derived angiogenesis inhibitors is well studied in animal models of cancer, their role in human cancers is less established. In this review we discuss the current knowledge about these molecules and their potential use as cancer therapeutics and biomarkers. © 2010 by the authors; licensee MDPI, Basel, Switzerland.

Cite

CITATION STYLE

APA

Sund, M., Nyberg, P., & Eikesdal, H. P. (2010). Endogenous matrix-derived inhibitors of angiogenesis. Pharmaceuticals. MDPI AG. https://doi.org/10.3390/ph3103021

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free